CUREVAC N.V. O.N.
Commented by André Will-Laudien on July 18th, 2022 | 15:04 CEST
Fall is coming: BioNTech, Defence Therapeutics, CureVac, Valneva - Which biotech stock will surge again?
The summer of rising incidences is making its way, but the public has already shelved the pandemic measures and hospitals are filling up again. Even if no one wants to talk about it anymore, the fourth wave is coming! Worldwide, the race for suitable vaccines or treatment methods continues. Medicine is still relatively helpless as far as treating severe cases is concerned, and the subject of post-COVID is considered completely unexplored. We take another critical look at the landscape of biotech stocks.Read
Commented by André Will-Laudien on June 30th, 2022 | 13:49 CEST
Biotech blockbusters: BioNTech, XPhyto Therapeutics, Valneva, CureVac - What to expect from these stocks?
Now that we have arrived in summer, the pandemic is weakening, and the media presence of the flu disease is also declining. That means less attention for pure-play vaccine makers, and now investors are asking how perhaps alternative money can be made. Is the pipeline of the protagonists strong enough to attract further investor capital, or will the whole industry go underground for the time being? We try our hand at being a truffle pig and dig beneath the surface. Which biotech stock has something up its sleeve?Read
Commented by André Will-Laudien on April 19th, 2022 | 10:49 CEST
The start of spring - and where to now? The mild flu outbreaks due to the Omicron variant and associated massive relaxations of Corona measures in many countries are weighing on the prospects of vaccine manufacturers in the short term. After all, there are no clinical bottlenecks, and the vaccination rate does not want to increase despite massive public campaigns. Mandatory vaccination is also off the table, and for the biotech industry and vaccine producers, this results in a need to keep researching other topics! Many diseases are more dangerous for us humans than Corona. We look at important protagonists.Read
Commented by André Will-Laudien on April 1st, 2022 | 12:43 CEST
With the Ukraine crisis, international vaccination activity has taken a back seat. The world's northern hemisphere is gearing up for next summer, so flu diseases are also slowly taking a back seat. However, the COVID virus will likely continue to mutate over the summer and will reappear in a new guise in the fall. Germany's maximum vaccination rate of 76% has been reached, with just under a quarter of the population ultimately foregoing vaccination after lengthy public measures. For the major biotech companies, it is now a case of - The country needs new products! There are still many areas of application in the field of mRNA. Which stocks stand out with their pipeline?Read
Commented by André Will-Laudien on March 21st, 2022 | 13:10 CET
The biotech sector, especially around vaccine manufacturers, has recently fallen somewhat out of fashion - Germany's most extensive Corona measures have likely already taken place. The general willingness to vaccinate can hardly be increased, and the vaccination obligation was dropped without a trace after lawyers formed a massive wave of lawsuits. But now that the Omicron infection figures are exploding to unimagined heights, we can expect a hot autumn again after a summer with a breather. "Corona has come to stay!" said Karl Lauterbach when he was not yet health minister. We take a look at some shares that have recently rebounded strongly.Read
Commented by André Will-Laudien on February 9th, 2022 | 12:22 CET
The biotech sector is a highly dynamic growth market within the equity universe. It is characterized by investment volumes of unprecedented size, which is also the reason for the high innovation rate characteristic of the sector. Price reactions to positive or negative surprises can be very volatile, and these tendencies are often exacerbated by the intervention of stop orders or the occurrence of derivative slippage. Vaccine manufacturers were down over 50% across the board, as the pandemic is being traded as a phase-out. The vaccination rate does not appear to be increasing significantly. Where are the opportunities for investors at the moment?Read
Commented by André Will-Laudien on November 3rd, 2021 | 13:26 CET
Healing and well-being are the focus of many biotech and pharmaceutical companies. In many cases, long research is carried out in order to get corresponding active substances on the way. After many clinical test series, the laborious approval process with the corresponding health authorities then begins. Some companies have provided themselves with good growth capital thanks to the high liquidity on the stock markets and are at the cutting edge with their products. We take a closer look at the industry.Read
Commented by Nico Popp on October 15th, 2021 | 10:10 CEST
The healthcare sector is facing a reassessment. For years, especially in Germany, health care has been "fiddled with" - a reform here, a change there, but in basic terms, little has changed in the system in recent years. With the new federal government, things could start to move. Regardless of ideological trench warfare, observers can state, especially under the impression of the pandemic, that innovative treatment methods and preventive care are the most important trends for the future, along with the digitization of the healthcare system. In this context, we present three companies and highlight their opportunities.Read
Commented by André Will-Laudien on October 14th, 2021 | 11:27 CEST
Biotechnology remains a hotly contested industry. In the fight against a wide range of diseases, biopharmaceuticals are the first port of call. It studies the relationship between drugs and excipients' chemical and physical properties and their form of administration in a living organism. By directly applying findings from biology and biochemistry, technically functional elements are identified. The central objectives are to research, improve and develop processes for the production of relevant substances. Often research goes nowhere; we take a look at the sector.Read
Commented by Armin Schulz on September 27th, 2021 | 13:24 CEST
The battle against the Coronavirus is still ongoing, although more and more people have been vaccinated with vector or mRNA vaccines. In Europe, an average of 60% of all people have received the vaccination. Herd immunity has not yet been achieved, in part because of vaccine skeptics who do not yet trust novel vaccines. New vaccines based on dead viruses promise to remedy the situation. This method has already been tried and tested in influenza vaccinations, for example. According to a study in Switzerland, about 70% of the unvaccinated would still be vaccinated if the method had already been tested. Herd immunity could thus be achieved, and everyday life could return to normal. So, which vaccine manufacturer that does not currently have an approved product could shake up the market?Read